Have a feature idea you'd love to see implemented?
Let us know!
AMPH Amphastar Pharmaceuticals Inc
Price (delayed)
$44.55
Market cap
$2.14B
P/E Ratio
13.71
Dividend/share
N/A
EPS
$3.25
Enterprise value
$2.58B
Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active
Highlights
The stock's P/E is 84% less than its 5-year quarterly average of 84.5 and 12% less than its last 4 quarters average of 15.5
Amphastar Pharmaceuticals's equity has increased by 22% YoY and by 2% from the previous quarter
Amphastar Pharmaceuticals's quick ratio has increased by 50% YoY but it has decreased by 3.9% QoQ
The net income has grown by 17% YoY but it has contracted by 5% from the previous quarter
Amphastar Pharmaceuticals's gross margin has decreased by 3.1% QoQ and by 2.2% YoY
Key stats
What are the main financial stats of AMPH
Market
Valuations
Earnings
Shares outstanding
48.08M
Market cap
$2.14B
Enterprise value
$2.58B
Price to earnings (P/E)
13.71
Price to book (P/B)
2.98
Price to sales (P/S)
2.99
EV/EBIT
11.75
EV/EBITDA
10.27
EV/Sales
3.57
Revenue
$723.55M
EBIT
$219.44M
EBITDA
$251.06M
Free cash flow
$170.15M
Per share
Balance sheet
Liquidity
EPS
$3.25
Free cash flow per share
$3.5
Book value per share
$14.95
Revenue per share
$14.88
TBVPS
$19.55
Total assets
$1.55B
Total liabilities
$817.5M
Debt
$629.85M
Equity
$727.68M
Working capital
$386.94M
Debt to equity
0.87
Current ratio
3.43
Quick ratio
2.47
Net debt/EBITDA
1.74
Margins
Efficiency
Dividend
EBITDA margin
34.7%
Gross margin
53%
Net margin
21.8%
Operating margin
29.6%
Return on assets
10.3%
Return on equity
22.9%
Return on invested capital
18.7%
Return on capital employed
15.8%
Return on sales
30.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AMPH stock price
How has the Amphastar Pharmaceuticals stock price performed over time
Intraday
1.04%
1 week
-1.13%
1 month
-12.34%
1 year
-21.36%
YTD
-27.97%
QTD
-8.2%
Financial performance
How have Amphastar Pharmaceuticals's revenue and profit performed over time
Revenue
$723.55M
Gross profit
$383.35M
Operating income
$214.26M
Net income
$157.72M
Gross margin
53%
Net margin
21.8%
Amphastar Pharmaceuticals's revenue has increased by 20% YoY
The company's gross profit rose by 18% YoY
The operating income has increased by 18% year-on-year but it has declined by 7% since the previous quarter
The net income has grown by 17% YoY but it has contracted by 5% from the previous quarter
Growth
What is Amphastar Pharmaceuticals's growth rate over time
Valuation
What is Amphastar Pharmaceuticals stock price valuation
P/E
13.71
P/B
2.98
P/S
2.99
EV/EBIT
11.75
EV/EBITDA
10.27
EV/Sales
3.57
The stock's P/E is 84% less than its 5-year quarterly average of 84.5 and 12% less than its last 4 quarters average of 15.5
The EPS has grown by 16% YoY but it has contracted by 5% from the previous quarter
Amphastar Pharmaceuticals's equity has increased by 22% YoY and by 2% from the previous quarter
The price to book (P/B) is 13% lower than the last 4 quarters average of 3.4
Amphastar Pharmaceuticals's revenue has increased by 20% YoY
AMPH's price to sales (P/S) is 13% less than its last 4 quarters average of 3.4 and 4.5% less than its 5-year quarterly average of 3.1
Efficiency
How efficient is Amphastar Pharmaceuticals business performance
The ROIC is down by 24% year-on-year and by 12% since the previous quarter
The company's return on assets fell by 16% YoY and by 6% QoQ
The ROS has contracted by 11% from the previous quarter and by 3.2% YoY
The ROE has contracted by 10% from the previous quarter and by 4.2% YoY
Dividends
What is AMPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AMPH.
Financial health
How did Amphastar Pharmaceuticals financials performed over time
The total assets is 89% greater than the total liabilities
Amphastar Pharmaceuticals's current ratio has soared by 63% YoY but it has decreased by 2.6% from the previous quarter
Amphastar Pharmaceuticals's quick ratio has increased by 50% YoY but it has decreased by 3.9% QoQ
AMPH's debt is 13% smaller than its equity
Amphastar Pharmaceuticals's debt to equity has decreased by 23% YoY
Amphastar Pharmaceuticals's equity has increased by 22% YoY and by 2% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.